The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up

May 1, 2021

The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.

A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)

Jan 1, 2020

Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.

The APHINITY Trial: Results of the Primary Analysis

Jul 13, 2017

An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.

The HERA Trial: Final Analysis Results

Feb 16, 2017

An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

Jul 1, 2016

JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.

The ALTTO Trial: Results of the Primary Analysis

Apr 1, 2016

An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

Sep 1, 2014

Findings from this study confirm that patients who achieve pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.

The HERA Trial: Cardiac Events at 8 years median follow-up

Jul 10, 2014

The JCO confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy.

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

Feb 18, 2012

An article in The Lancet reporting that dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

Jun 1, 2008

The Annals of Oncology presents the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

FRONTIER SCIENCE | PUBLICATIONS

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

TITLE OF PUBLICATION

AUTHORS

PUBLICATION REFERENCE

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up

A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)

The APHINITY Trial: Results of the Primary Analysis

The HERA Trial: Final Analysis Results

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

The ALTTO Trial: Results of the Primary Analysis

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

The HERA Trial: Cardiac Events at 8 years median follow-up

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups